Aligos Therapeutics, Inc. (ALGS)
After hours:
- Simply Wall St.
Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
Aligos Therapeutics ( NASDAQ:ALGS ) First Quarter 2024 Results Key Financial Results Revenue: US$986.0k (down 64% from...
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the first quarter 2024. “We have executed on a number of key deliverables to position Aligos for success,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President & CEO of Aligo
- GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical comp
